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Previous literature suggests that the recurrence of
focal segmental glomerulosclerosis (FSGS) after renal
transplantation is more common in recipients who
have received an HLA-identical living-related (LRD)
transplant. To address the question if FSGS patients
can safely receive a 6-antigen match LRD kidney trans-
plant, we analyzed death-censored renal allograft sur-
vival data of FSGS patients from the United States Re-
nal Data System database (USRDS).
Using the USRDS and the U.S. Scientific Renal Trans-
plant Registry between the years 1988–97, we found
19259 adult primary renal transplant recipients, of
which 2414 patients had FSGS as their primary diag-
nosis as compared to 16845 patients who had other
types of glomerulonephritis (GN). A Cox proportional
hazard model was used to estimate death-censored
graft survival among FSGS patients with a zero mis-
match LRD kidney transplant. The model included a
triple interaction term comparing FSGS vs. GN vs.
living donation (LD) vs. cadaveric donation (CAD) vs.
zero mismatch (six antigen or HLA-identical) vs. mis-
match. Annually adjusted death censored graft loss
rates per 1000 patients (ADGL) were calculated.
Focal segmental glomerulosclerosis patients receiving
a zero mismatch LRD kidney transplant had the lowest
ADGL rate, losing 10.5 grafts per 1000 patients per
year. Not significantly different but higher (14.3) was
the ADGL rate for LD, zero mismatch GN recipients.
The ADGL rate was significantly higher in FSGS recipi-
ents who received a LD, mismatched transplant (36.5).
Focal segmental glomerulosclerosis patients who re-
ceived a CAD, zero mismatched graft (44.1), or CAD,
mismatched graft (63.2), had significantly higher
ADGL rates.
Zero mismatch LRD kidney transplants are not a risk
factor for graft loss in FSGS patients but are associated
with significantly better death-censored graft survival
as compared to CAD 6-antigen match or mismatched
donations.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is a common
cause of nephrotic syndrome in the United States (1). The
pathogenesis of FSGS remains unclear but has been attri-
buted to a ‘circulating factor’ present in the serum of patients
with FSGS (2). Recurrence of FSGS after transplantation is
not unusual and is most likely to occur in those recipients
who have progressed rapidly to end-stage renal disease
(ESRD) from the time of diagnosis (3). Post-transplantation
recurrence of FSGS in the kidney allograft can occur in up to
50% of renal allografts (4). In addition, allograft failure from
recurrent FSGS is significant with the relative risk for graft
loss of 2.25 and the 5-year kidney survival rate of 34.2% for
transplant recipients with recurrent FSGS (5). Attempts have
been made to remove the ‘FSGS factor’ with plasmapheresis
before renal transplantation or peri-operatively with variable
success (6). Because of the substantial risk of renal allograft
loss from recurrence of FSGS, it has been recommended that
live donation be avoided (7).
Historically and today, FSGS patients have received kidney
transplants from living-related donors (LRD). Surveying
89U.S. transplant centers in the late 1970s, Zimmerman re-
ported an 82% incidence of recurrent FSGS in transplant re-
cipients who received at least a 4-antigen-matched LRD
transplant, and concluded that HLA-identical sibling trans-
plants should be avoided in this population (8). Subsequently,
Morzycka et al. suggested that recurrent FSGS was more
common in those renal transplant recipients who received
LRD transplants (9). Current reference literature on renal
transplantation continues to suggest that LRD transplants for
patients with FSGS have a high rate of recurrence and hence,
portend a worse outcome with such transplants as opposed
to cadaveric transplants (10,11). Several groups have exam-
ined graft loss from recurrent FSGS with conflicting results
(12,13). The above-mentioned studies suggest that recur-
rence of FSGS is more common in LRD and zero mismatch
kidney transplants as compared to cadaveric and unmatched
kidney transplants. As mentioned earlier, as recurrence of
FSGS has been related to worse graft survival, these data
suggest that a zero mismatch LRD kidney transplant should
be avoided in patients with ESRD secondary to FSGS. In fact,
this recommendation is widely held by U.S. transplant cen-
ters.
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Table1: Cox model for death-censored graft loss
Disease Donor Number of patients Match RR 95% CI
GN LD 979 Full ref. –
GN CAD 436 Full 2.01 1.51–2.68
GN LD 4017 Mis 2.06 1.65–2.57
GN CAD 11413 Mis 3.77 3.03–4.69
FSGS LD 136 Full 0.78 0.39–1.54
FSGS CAD 72 Full 1.88 1.09–3.26
FSGS LD 624 Mis 2.53 1.89–3.39
FSGS CAD 1582 Mis 4.47 3.53–5.66
GNΩglomerulonephritis, FSGSΩ focal segmental glomerulosclerosis, LDΩ living donor, CADΩcadaveric donation.
On the other hand, it has been documented previously in the
literature that graft survival among LRD transplant recipients
is superior to the graft survival of cadaveric (CAD) transplants,
and that well-matched renal allografts have superior graft sur-
vival as compared to mismatched grafts (14). To determine
whether the potentially higher risk for recurrence of FSGS
outweighs the benefits of receiving a living related and/or
well-matched kidney transplant, we examined the death-cen-
sored graft survival rates among FSGS patients held in the
United States Renal Data System (USRDS) database. Thus,
we used death-censored graft survival as the final study end-
point and not recurrence of FSGS.
Methods
To evaluate renal allograft survival in FSGS patients who received a zero mis-
match LRD transplant, we analyzed 19259 adult primary renal transplant re-
cipients registered in the USRDS database between 1988 and 1997. Of
these patients, 2414 recipients had FSGS as their primary diagnosis as com-
pared to 16845 patients with glomerulonephritis (GN). Glomerulonephritis
patients were used as the reference population, as these patients were felt
most likely to reflect a homogeneous population of patients without pre-
existing comorbidities, similar to those patients with FSGS.
A Cox proportional hazard model was used to estimate the adjusted death-
censored graft survival among FSGS and GN patients who received a zero
mismatch LRD transplant. Estimates of graft survival among FSGS and GN
patients were also obtained for HLA-mismatched LRD transplants, zero
mismatch CAD transplants, and HLA-mismatched CAD transplants. A
triple interaction term was included in the Cox model to look at the poten-
tial for effect-modification between FSGS vs. GN vs. living donation vs.
CAD vs. zero mismatch (HLA-identical or 6-antigen match) vs. HLA-mis-
match. In addition, the Cox model was adjusted for 11 covariates relevant
to death-censored graft survival including donor and recipient age, recipi-
ent gender and race, panel reactive antibody (PRA), cold ischemic time
(CIT), year of transplantation, time on dialysis, induction, calcineurin inhi-
bition (FK506 vs. cyclosporine), and antiproliferative agents (azathioprine
vs. mycophenolate mofetil). The primary study endpoint was adjusted
death-censored graft survival. Patients were studied until graft loss, death,
or loss to follow up, in which time they were censored. A probability of
type 1 error (a)Ω0.05 was considered to be the threshold of statistical
significance. All statistical analyses were performed using SPSS software
(version 10.0 for Windows 95; SPSS Inc., Chicago, IL).
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Results
Table1 displays the interaction terms for the Cox proportional
hazard model for death-censored graft survival. Causes of
ESRD that received a living donated (LD) kidney transplant
are depicted in bold lettering as compared to those that re-
ceived a CAD kidney transplant. In this model, GN patients
who received a zero mismatch LD kidney transplant were
considered as the reference group. Focal segmental glomeru-
losclerosis patients who received a zero mismatch LD kidney
transplant had equivalent death-censored graft survival as
compared to GN patients with a zero mismatch LD transplant
(p-value not significant). In contrast to the GN patients with
a zero mismatch LD transplant, GN and FSGS recipients who
received a zero mismatch CAD renal transplant had signifi-
cantly worse death-censored graft survival. Focal segmental
glomerulosclerosis and GN patients who received a mis-
matched LD renal transplant had significantly worse death-
censored graft survival, as did those FSGS and GN patients
who received a mismatched CAD renal transplant. The rela-
tive risk of graft failure for FSGS patients who received a mis-
matched cadaveric renal transplant was more than three-fold
higher than the GN reference group. Compared with FSGS
patients receiving a zero mismatch LD renal transplant, FSGS
patients who received a mismatched cadaveric kidney trans-
plant had dramatically worse death-censored graft survival.
Figure1 shows the differences in death-censored graft sur-
vival among FSGS and GN patients who received either a
zero mismatched or a mismatched CAD or LD renal trans-
plant. As shown in Figure 2, death-censored graft survival is
similar among GN and FSGS patients who received a zero
mismatch LD kidney transplant. Conversely, GN and FSGS
patients who received a mismatched CAD kidney transplant
had poor five-year graft survival. Thus, FSGS patients who
received a zero mismatch LD kidney transplant had 15%
better graft survival than those FSGS patients who received
a zero mismatch CAD kidney transplant. Additionally, death-
censored graft survival was 22% better in the FSGS recipi-
ents who received a zero mismatch LD renal transplant as
compared to those FSGS recipients who received a mis-
matched CAD renal transplant.
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Figure1: Five-year death-censored renal allograft survival in
renal transplant recipients with either focal segmental glo-
merulosclerosis (FSGS) or glomerulonephritis and with
either a zero mismatch or a HLA-mismatch vs. cadaveric do-
nation or living donor (LD) kidney transplant
Figure2: Five-year death-censored renal allograft survival in
renal transplant recipients with focal segmental glomeru-
losclerosis (FSGS) and with either a zero mismatch, living
donor (LD) kidney transplant; an HLA-mismatch, LD kidney
transplant; a zero mismatch, cadaveric (CAD) kidney trans-
plant; or an HLA-mismatch, CAD kidney transplant. GNΩ
glomerulonephritis
Figure2 shows the death-censored graft survival among
FSGS patients who received either a zero mismatched or a
mismatched LD renal transplant as compared to those FSGS
patients who received either a zero mismatched or a mis-
matched CAD renal transplant. Focal segmental glomeru-
losclerosis recipients who received a zero mismatch LD kid-
ney transplant had significantly superior death-censored
graft survival (95%) as compared to those FSGS recipients
who received either a mismatch LD renal transplant (83.1%)
or either a zero mismatched or a mismatched CAD renal
transplant (80.2% vs. 72.9%, respectively).
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Table2: Annually adjusted graft loss rates (per 1000 patient-years)
FSGS LD 0MM Rates
Yes yes yes 10.5
No yes yes 14.3
No no yes 27.9
No yes no 29.7
Yes yes no 36.5
Yes no yes 44.1
No no no 53.6
Yes no no 63.2
0-MM is zero mismatch or a 6-antigen match kidney transplant.
FSGSΩ focal segmental glomerulosclerosis, LDΩ living donor.
Table3: Cox proportional hazard model covariates for death-cen-
sored graft survival
RR 95% CI p-value
Recipient age 0.999 0.997–1.002 0.667
Recipient gender 1.002 0.940–1.067 0.956
African American 1.870 1.745–2.005 0.0001
MMF 0.793 0.664–0.948 0.011
FK506 1.020 0.849–1.226 0.831
Induction 1.069 0.769–1.488 0.691
CIT (h) 1.004 1.001–1.007 0.019
PRA (%) 1.004 1.003–1.006 0.0001
Donor age 1.014 1.012–1.016 0.0001
Adjusted for time on dialysis; reference group for African American
race is Caucasian cohort; reference group for MMF is azathioprine;
reference group for FK506 is cyclosporine.
PRAΩpanel reactive antibody, CINΩcold ischemic time,
MMFΩmycophenolate mofetil.
Annually adjusted graft loss rates calculated from the Cox
model are displayed in Table2. For FSGS patients with a zero
mismatch LD renal transplant, the annually adjusted graft loss
rate was 10.5 per 1000 patient-years as compared to the GN
reference group whose annually adjusted graft loss rate was
14.3 per 1000 patient-years. In comparison, those FSGS pa-
tients who received a mismatched LD renal transplant had
an annually adjusted graft loss rate of 36.5 per 1000 patient-
years. In contrast, the FSGS patients with a zero mismatch
CAD renal transplant or with a mismatched CAD renal trans-
plant had annually adjusted graft loss rates of 44.1 per 1000
patient-years and 63.2 per 1000 patient-years, respectively.
Covariates for the Cox proportional hazard model for death-
censored graft survival are shown in Table3. Of the 11 covar-
iates in the model, donor age, PRA, CIT, African American
race, and time on dialysis (data not shown) were significant
risk factors for death-censored graft failure. In contrast, my-
cophenolate mofetil was a significant protective factor
against death-censored graft failure. Recipient age and gen-
der, induction, and FK506 were not significant factors for
death-censored graft survival.
Discussion
Currently in some centers, zero mismatch LD kidney trans-
plantation has been avoided in FSGS patients for fear that
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recurrent FSGS in the renal allograft would lead to premature
graft loss, even though graft survival among LRD transplant
recipients is superior in well-matched grafts and is far su-
perior to the graft survival rate among CAD transplant recipi-
ents. In contrast to this widespread concept, our study dem-
onstrates superior death-censored graft survival for FSGS pa-
tients who received a zero mismatch LD kidney transplant
as compared to those FSGS patients who received an HLA-
mismatched cadaveric kidney transplant. Furthermore, the
FSGS patients who received a zero mismatch LD kidney
transplant had similar death-censored graft survival as com-
pared to the GN patients with a zero mismatch LD kidney
transplant. Glomerulonephritis patients were used as the ref-
erence population because these patients reflect a homoge-
neous population of patients without pre-existing comorbid-
ities, similar to those patients with FSGS. In addition, among
patients with ESRD, GN patients have been demonstrated
to have superior death-censored graft survival (15,16), so we
compared our FSGS cohort to a reference population known
to have excellent renal allograft survival.
As mentioned earlier, previous studies and current literature
on renal transplantation suggest that LRD transplants for pa-
tients with FSGS give a high rate of recurrence and hence,
portend a worse outcome as opposed to cadaveric renal
transplants. As recurrence of FSGS has been related to worse
graft survival, these studies suggest that a zero mismatch
LRD kidney transplant should be avoided in patients with
ESRD from FSGS. In fact, this recommendation is widely held
by U.S. transplant centers today. Although our data does not
address the incidence of recurrent FSGS in patients with a
LRD kidney transplant, it does address renal allograft survival
in FSGS patients who received a LD kidney transplant as
compared to those FSGS patients who received a cadaveric
kidney transplant. In addition, we address the issue of graft
survival in those FSGS patients who received a zero mis-
match LD kidney transplant. Censoring for death, our data
shows that FSGS patients who had a zero mismatch LD kid-
ney transplant had significantly superior graft survival over
FSGS patients who received either a zero mismatch or HLA-
mismatch CAD kidney transplant. Therefore, ESRD patients
with FSGS benefit from live donation and a zero mismatch,
and, if possible, should receive a zero mismatch LD kidney
transplant to maximize chances for long-term graft survival.
As with any retrospective analysis, there are limitations to the
study. It cannot be determined if the diagnosis of FSGS was
biopsy-proven, even though it is unlikely to assume that any
nephrologist would diagnose FSGS as the primary cause of
ESRD without a biopsy. In addition, some secondary causes
of FSGS may have been recorded as the primary cause of
ESRD. Causes of graft loss and incidence of recurrence have
been reported previously and hence were not the focus of
our analysis (12,13).
In summary, zero mismatch LRD kidney transplants are not a
risk factor for graft loss in FSGS patients but are associated
with significantly better death-censored renal allograft sur
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-vival as compared to cadaveric zero mismatch or HLA-mis-
match donations.
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